Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure

International Journal of Hematology

Volumn 83, Issue 3, 2006, Pages 238-242

  Zver, Samo ^a   Zupan, Irena Preloznik ^a   Cernelc, Peter ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Autoimmune thrombocytopenic purpura; Cyclosporin A; Splenectomy

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; CYCLOSPORIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIC PURPURA; CHRONIC DISEASE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; LEG EDEMA; MAINTENANCE THERAPY; MALE; MUCOSAL BLEEDING; PATIENT SATISFACTION; RELAPSE; REMISSION; SPLENECTOMY; SUBCUTANEOUS TISSUE; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT OUTCOME; BLEEDING; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; EDEMA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MIDDLE AGED; SALVAGE THERAPY;

ADRENAL CORTEX HORMONES; ADULT; AGED; CHRONIC DISEASE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; EDEMA; FEMALE; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; SALVAGE THERAPY; SPLENECTOMY;

EID: 33745953049     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05149     Document Type: Article

References (21)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
2. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88:194-201.
3. Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999;104:442-447.
4. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393-1402.
5. Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci. 1998;19:245-251.
6. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol. 2002;118:933-944.
7. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol. 2002;81:312-319.
8. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99:1482-1485.
9. Stasi R, Pagana A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-957.
10. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117:712-715.
11. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-898.
12. Schattner E, Bussel J. Mortality in immune thrombocytopenic purpura: report of seven cases and consideration of prognostic indicators. Am J Hematol. 1994;46:120-126.
13. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77:31-33.
14. Portielje JEA, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549-2554.
15. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630-1638.
16. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
17. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320:974-980.
18. Peng J, Chuanfang L, Liu D, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood. 2003;101:2721-2726.
19. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725-1738.
20. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114:121-125.
21. Schultz KR, Strahlendorf C, Warrier I, Ravindranath Y. Cyclosporin A therapy of immune-mediated thrombocytopenia in children. Blood. 1995;85:1406-1408.